Clinical effects of long-term cardiac contractility modulation (CCM) in subjects with heart failure caused by left ventricular systolic dysfunction.

Autor: Müller D; Heart and Vascular Center (HGZ), Bad Bevensen, Germany., Remppis A; Heart and Vascular Center (HGZ), Bad Bevensen, Germany. ba.remppis@hgz-bb.de., Schauerte P; University Hospital Aachen RWTH, Berlin, Germany., Schmidt-Schweda S; Georg August University of Gottingen, Gottingen, Germany., Burkhoff D; Columbia University, New York, NY, USA., Rousso B; Impulse Dynamics, Hod Hasharon, Israel., Gutterman D; Medical College of Wisconsin, Milwaukee, WI, USA., Senges J; Institut für Herzinfarktforschung, Ludwigshafen, Germany., Hindricks G; Heart Center Leipzig, Leipzig, Germany., Kuck KH; Asklepios Klinik St. Georg, Hamburg, Germany.
Jazyk: angličtina
Zdroj: Clinical research in cardiology : official journal of the German Cardiac Society [Clin Res Cardiol] 2017 Nov; Vol. 106 (11), pp. 893-904. Date of Electronic Publication: 2017 Jul 06.
DOI: 10.1007/s00392-017-1135-9
Abstrakt: Introduction: Heart failure is a major cause of morbidity and mortality throughout the world. Despite advances in therapy, nearly half of patients receiving guideline-directed medical therapy remain limited by symptoms. Cardiac contractility modulation (CCM) can improve symptoms in this population, but efficacy and safety in prospective studies has been limited to 12 months of follow-up. We report on the first 2 year multi-site evaluation of CCM in patients with heart failure.
Methods: One hundred and forty-three subjects with heart failure and reduced ejection fraction were followed via clinical registry for 24 months recording NYHA class, MLWHFQ score, 6 min walk distance, LVEF, and peak VO 2 at baseline and 6 month intervals as clinically indicated. Serious adverse events, and all cause as well as cardiovascular mortality were recorded. Data are presented stratified by LVEF (all subjects, LVEF <35%, LVEF ≥35%).
Results: One hundred and six subjects from 24 sites completed the 24 month follow-up. Baseline parameters were similar among LVEF groups. NYHA and MLWHFQ improved in all 3 groups at each time point. LVEF in the entire cohort improved 2.5, 2.9, 5.0, and 4.9% at 6, 12, 18, and 24 months, respectively. Insufficient numbers of subjects had follow-up data for 6 min walk or peak VO 2 assessment, precluding comparative analysis. Serious adverse events (n = 193) were observed in 91 subjects and similarly distributed between groups with LVEF <35% and LVEF ≥35%, and similar to other device trials for heart failure. Eighteen deaths (7 cardiovascularly related) over 2 years. Overall survival at 2 years was 86.4% (95% confidence intervals: 79.3, 91.2%).
Conclusion: Cardiac contractility modulation provides safe and effective long-term symptomatic and functional improvement in heart failure. These benefits were independent of baseline LVEF and were associated with a safety profile similar to published device trials.
Databáze: MEDLINE
Externí odkaz: